SYNT 002

Drug Profile

SYNT 002

Alternative Names: SYNT-002

Latest Information Update: 28 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Syntimmune
  • Class
  • Mechanism of Action Fc receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Metabolic disorders

Most Recent Events

  • 20 Mar 2017 Preclinical trials in Metabolic disorders in USA (unspecified route) before March 2017
  • 20 Mar 2017 Syntimmune plans IND-enabling trials for SYNT 002 in 2017
  • 20 Mar 2017 Pharmacodynamics data from a preclinical trial in Metabolic disorders released by Syntimmune
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top